ReviewNature reviews. Immunology2007
Rethinking peptide supply to MHC class I molecules.
Review in Nature reviews. Immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Assessing the generalization capabilities of TCR binding predictors via peptide distance analysis.PloS one · 2025Article
- Role of cross-reactivity in cellular immune targeting of influenza A M1Frontiers in immunology · 2022Article
- Kinetically distinct processing pathways diversify the CD8Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Islet stress, degradation and autoimmunity.Diabetes, obesity & metabolism · 2018Review
- The canine MHC class Ia allele DLA-88*508:01 presents diverse self- and canine distemper virus-origin peptides of varying length that have a conserved binding motif.Veterinary immunology and immunopathology · 2018Article
- Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.Cellular and molecular life sciences : CMLS · 2018Review
- Elucidation of Gene Expression Patterns in the Brain after Spinal Cord Injury.Cell transplantation · 2017Article
- MHC class I-associated peptides derive from selective regions of the human genome.The Journal of clinical investigation · 2016Article
- Defining Viral Defective Ribosomal Products: Standard and Alternative Translation Initiation Events Generate a Common Peptide from Influenza A Virus M2 and M1 mRNAs.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- The presence of prolines in the flanking region of an immunodominant HIV-2 gag epitope influences the quality and quantity of the epitope generated.European journal of immunology · 2015Article
- The nature and extent of contributions by defective ribosome products to the HLA peptidome.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.Journal of leukocyte biology · 2014Review
- The peptide-receptive transition state of MHC class I molecules: insight from structure and molecular dynamics.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.Trends in immunology · 2011Review
- Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands.Cellular and molecular life sciences : CMLS · 2011Review
- Hydrophobicity as a driver of MHC class I antigen processing.The EMBO journal · 2011Article
- HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.Immunogenetics · 2011Article
- Cutting Edge: Selective role of ubiquitin in MHC class I antigen presentation.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The notion that peptides bound to MHC class I molecules are derived mainly from newly synthesized proteins that are defective, and are therefore targeted for immediate degradation, has gained wide acceptance. This model, still entirely hypothetical, has strong intuitive appeal and is consistent with some experimental results, but it is strained by other findings, as well as by established and emerging concepts in protein quality control. While not discounting defectiveness as a driving force for the processing of some proteins, we propose that MHC-class-I-restricted epitopes are derived mainly from nascent proteins that are accessed by the degradation machinery prior to any assessment of fitness, and we outline one way in which this could be accomplished.
Indexed as
Identifiers
17457346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.